Algo version: 0.98b
Dishman Carbogen Amcis is listed at the NSE Exchange
Dishman Carbogen Amcis [DCAL.NS]
NSE Sector: Healthcare Industry:Biotechnology

Is Dishman Carbogen Amcis stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

Yes, Dishman Carbogen Amcis pays dividends. Last time was Thursday 24th of October 2019 where the investors holding the stock on Thursday 12th of September 2019 were paid INR0.2 per share. Over the last 15 times between 2004 and 2019, Dishman Carbogen Amcis has paid INR19.8 with an average of INR1.32 per share.

Sorry, we do not have any analyst data for this ticker

We cannot find data for Dishman Carbogen Amcis 10 years ago, but if you had invested on Monday 9th of September 2019 when the price was INR179.50, you would have made a profit of INR18.58 per share or 10.35%

Yes, the average daily trading liquidity for Dishman Carbogen Amcis is INR1.01 million. You should therefore be able to get in and out of your positions relatively fast.

Dishman Carbogen Amcis has a normal ratio of the business financed by loans. This puts the company at some risk in periods of high inflation where borrowing costs usually go up. With a normal cash flow to debt ratio of 0.30, the company's ability to pay off the debt is normal. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.

We have calculated the inflation risk for Dishman Carbogen Amcis to be medium [0.6 of 1]

US inflation for July 2024 was 0.15%. Over the last 12 months, the US inflation is 2.92%. The 10-year treasury yield that indicates the future interest level is currently 3.72 and is down -0.95 over the last 30 days.